UK pharma major GlaxoSmithKline (LSE: GSK) and US partner Innoviva (Nasdaq: INVA) have presented positive new data on their Breo Ellipta (fluticasone furoate/vilanterol or FF/VI 100/25mcg) for chronic obstructive pulmonary disease (COPD).
The data, which was presented at the American Thoracic Society (ATS) Conference, is from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial, which failed to meet its primary endpoint.
One analysis demonstrated that patients with COPD and moderate airflow limitation receiving Breo Ellipta achieved improvements in exacerbations compared with placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze